Novartis Company Profile

What is the competitive landscape for NOVARTIS

NOVARTIS has one hundred and eighty-eight approved drugs.

There are one hundred and twenty-six US patents protecting NOVARTIS drugs.

There are two thousand eight hundred and seventy-eight patent family members on NOVARTIS drugs in sixty-five countries and five hundred and sixty-six supplementary protection certificates in twenty countries.

Summary for Novartis

International Patents:	2878
US Patents:	126
Tradenames:	156
Ingredients:	140
NDAs:	188
Drug Master File Entries:	1
Patent Litigation for Novartis:	See patent lawsuits for Novartis
PTAB Cases with Novartis as patent owner:	See PTAB cases with Novartis as patent owner

Drugs and US Patents for Novartis

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	SLOW-K	potassium chloride	TABLET, EXTENDED RELEASE;ORAL	017476-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Novartis	NEXCEDE	ketoprofen	FILM;ORAL	022470-001	Nov 25, 2009		DISCN	No	No
Novartis	PROMACTA KIT	eltrombopag olamine	FOR SUSPENSION;ORAL	207027-001	Aug 24, 2015	AB	RX	Yes	Yes	7,547,719*PED				Y
Novartis	MEKINIST	trametinib dimethyl sulfoxide	TABLET;ORAL	204114-003	May 29, 2013		RX	Yes	Yes	10,869,869*PED				Y

Expired US Patents for Novartis

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	LOPRESSOR	metoprolol fumarate	TABLET, EXTENDED RELEASE;ORAL	019786-003	Dec 27, 1989	4,892,739
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-004	Feb 27, 1996	4,849,226
Novartis	AFINITOR	everolimus	TABLET;ORAL	022334-003	Jul 9, 2010	5,665,772*PED
Novartis	ARCAPTA NEOHALER	indacaterol maleate	POWDER;INHALATION	022383-001	Jul 1, 2011	8,796,307

Paragraph IV (Patent) Challenges for NOVARTIS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	10 mg		2014-06-18
	Capsules	0.5 mg		2014-09-22
	Tablets	2.5 mg		2006-03-02
	Tablets	80 mg/12.5 mg, 160 mg/12.5 mg and 160 mg/25 mg		2005-12-02
	Capsules	400 mg		2014-01-24
	Tablets	180 mg		2015-10-23
	Tablets	5 mg/160 mg		2007-10-22
	Capsules	150 mg and 200 mg		2013-01-29
	Tablets	10 mg/160 mg		2007-10-01
	Injection	4 mg/100 mg, 100 mL vial		2012-01-31
	Tablets	5 mg/12.5 mg/160 mg, 5 mg/25 mg/160 mg, 10 mg/25 mg/160 mg and 10 mg/25 mg/320 m		2009-09-14
	Nasal Spray	0.665 mg/ Spray		2009-06-29
	Tablets	125 mg, 250 mg and 500 mg		2004-12-28
	Oral Suspension	300 mg/5 mL		2006-12-26
	Tablets	12.5 mg and 25 mg		2014-02-04
	Delayed-release Tablets	180 mg		2009-06-04
	Capsules	1.5 mg, 3 mg, 4.5 mg and 6 mg		2004-04-21
	Tablets	250 mg		2011-03-14
	Tablets	125 mg, 250 mg, and 500 mg		2011-10-28
	Transdermal System Extended-release	13.3 mg/24 hr		2013-01-22
	Tablets for Oral Suspension	2 mg, 3 mg and 5 mg		2016-12-30
	Tablets	2.5 mg, 5 mg, and 7.5 mg		2014-12-10
	Tablets	100 mg and 400 mg		2007-03-12
	Tablets	90 mg and 360 mg		2015-10-19
	Tablets	320 mg/12.5 mg and 320 mg/25 mg		2007-02-07
	Capsules	20 mg and 40 mg		2008-06-04
	Tablets	180 mg		2016-04-28
	Tablets	5 mg/320 mg		2007-11-26
	Injection	0.8 mg (base) /mL		2008-06-11
	Tablets	10 mg/320 mg		2007-11-09
	Ophthalmic Solution	0.003%		2015-12-30
	Tablets	10 mg/12.5 mg/160 mg		2009-10-22
	Tablets	150 mg, 300 mg and 600 mg		2006-05-05
	Tablets	50 mg and 75 mg		2014-01-07
	Delayed-release Tablets	360 mg		2009-02-02
	Tablets	40 mg, 80 mg,160 mg		2004-12-28
	Tablets	60 mg and 120 mg		2004-12-22
	Extended-release Tablets	100 mg		2005-12-30
	Oral Solution	2 mg/mL		2004-11-05
	Tablets	0.25 mg, 0.5 mg, and 0.75 mg		2013-09-30

International Patents for Novartis Drugs

Country	Patent Number	Estimated Expiration
Denmark	1638574
Philippines	12016502272
South Korea	101356748
Japan	2025020368

Supplementary Protection Certificates for Novartis Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2269604	93320	Luxembourg		PRODUCT NAME: EVEROLIMUS OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/09/538-001-006 - AFINITOR - EVEROLIMUS
0678503	C300499	Netherlands		PRODUCT NAME: COMBINATIE OMVATTEND ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110114
0678503	C300296	Netherlands		PRODUCT NAME: ALISKIREN OF EEN; REGISTRATION NO/DATE: EU/1/07/405/001-020 20070822
2331537	20C1055	France		EPRODUCT NAME: ALPELISIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, REGISTRATION NO/DATE: EU/1/20/1455 20200728

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Nova Labs Ltd
• Nova Pneuma
• Novadaq Tech
• Novartis

Novartis Competitive Landscape Analysis: Market Position, Strengths & Strategic Insights

Last updated: February 19, 2026

Novartis holds a significant position in the global pharmaceutical market, driven by its diversified portfolio, robust R&D pipeline, and strategic acquisitions. The company's performance is benchmarked against key competitors including Roche, Pfizer, and Merck & Co., across therapeutic areas such as oncology, immunology, and cardiovascular disease.

What is Novartis's Current Market Standing?

Novartis's market standing is characterized by consistent revenue generation and a strong presence in key therapeutic segments. In 2023, the company reported net sales of $45.5 billion, a slight decrease from $49.5 billion in 2022, primarily attributed to the divestment of its Sandoz generics business [1]. Despite this, Novartis maintains a leading position in several high-value markets.

Key Revenue Drivers (2023)

• Oncology: This segment remains a cornerstone, with key products contributing substantial revenue.
• Cardiovascular, Renal, and Metabolism (CRM): This area shows consistent performance.
• Immunology: Growing contributions from new and established therapies.
• Neuroscience: Emerging as a significant growth area.

Table 1: Novartis Net Sales by Therapeutic Area (2023)

Therapeutic Area	Net Sales (USD Billion)	Year-over-Year Change
Oncology	15.0	-3%
Cardiovascular, Renal & Metabolism	11.2	+11%
Immunology	7.8	+8%
Neuroscience	6.5	+15%
Other	5.0	N/A
Total Net Sales	45.5	-8%

Source: Novartis Annual Report 2023 [1]

Competitor Benchmarking (2023 Net Sales)

Comparing Novartis's net sales with direct competitors provides context for its market position.

Table 2: Competitor Net Sales Comparison (2023, USD Billion)

Company	Net Sales
Novartis	45.5
Roche	64.3
Pfizer	58.5
Merck & Co.	60.1

Sources: Novartis Annual Report 2023 [1], Roche Annual Report 2023 [2], Pfizer Annual Report 2023 [3], Merck & Co. Annual Report 2023 [4]

What are Novartis's Core Strengths?

Novartis possesses several strategic strengths that underpin its competitive advantage and future growth prospects. These include a diversified product portfolio, a robust R&D engine with a focus on innovation, and effective strategic partnerships and acquisitions.

Diversified Product Portfolio

Novartis has deliberately diversified its revenue streams across multiple therapeutic areas. This diversification mitigates risks associated with reliance on a single blockbuster drug and positions the company to capitalize on trends in different disease areas. Key therapeutic areas with strong product portfolios include:

• Oncology: Novartis maintains a leading position with established and emerging oncology therapies. Key products include Kisqali (ribociclib) for breast cancer, Tabrecta (capmatinib) for non-small cell lung cancer, and Scemblix (asciminib) for chronic myeloid leukemia [1].
• Cardiovascular, Renal and Metabolism (CRM): Entresto (sacubitril/valsartan) for heart failure has been a significant growth driver. The segment also includes other cardiovascular and metabolic treatments [1].
• Immunology: Cosentyx (secukinumab) for psoriasis, psoriatic arthritis, and ankylosing spondylitis is a flagship product. Other immunology assets address conditions like asthma and uveitis [1].
• Neuroscience: This segment is gaining momentum with treatments for conditions such as multiple sclerosis and spinal muscular atrophy [1].

The company's ability to manage and grow these diverse segments allows for cross-functional learning and resource allocation, strengthening its overall market resilience.

Robust Research and Development Pipeline

Novartis's commitment to innovation is reflected in its significant investment in R&D. The company focuses on developing novel therapies for unmet medical needs, particularly in areas with high growth potential and limited treatment options.

R&D Investment: Novartis consistently allocates a substantial portion of its revenue to R&D, aiming to discover and develop next-generation medicines. In 2023, R&D expenses were $10.5 billion, representing approximately 23% of net sales [1]. This investment supports both internal discovery efforts and external collaborations.

Pipeline Focus Areas:

• Gene Therapies: Novartis is a pioneer in gene therapy with Kymriah (tisagenlecleucel), a CAR-T therapy for certain blood cancers. The company continues to explore the potential of gene therapies for other indications [1].
• Advanced Modalities: The pipeline includes significant efforts in areas such as small molecules, biologics, radioligands, and RNA-based therapies.
• Oncology Innovation: Continued focus on precision oncology, including targeted therapies and immunotherapies.
• Cardiovascular and Metabolic Diseases: Development of novel treatments addressing a wide range of cardiovascular conditions.
• Neuroscience: Expansion of its portfolio for neurological disorders.

The company's R&D strategy emphasizes high-potential assets and the application of cutting-edge science, aiming to secure future revenue streams and address significant patient needs.

Strategic Acquisitions and Partnerships

Novartis strategically utilizes acquisitions and partnerships to enhance its pipeline, access new technologies, and expand its market reach.

Key Strategic Moves:

• Acquisition of Karyopharm Therapeutics' Selinexor (2024): While still in early stages, this acquisition signals continued interest in oncology [5].
• Acquisition of Cytokinetics (Ongoing Bid in 2024): A bid for Cytokinetics demonstrates an interest in cardiovascular therapies, specifically troponic activators [6].
• AbbVie Collaboration (2023): Partnership to co-develop and co-commercialize therapies for neglected tropical diseases, underscoring a commitment to global health [7].
• Divestment of Sandoz (2023): The separation of the generics division allowed Novartis to sharpen its focus on innovative medicines and advanced therapies [1].

These strategic maneuvers allow Novartis to rapidly acquire promising assets, offload non-core businesses, and leverage external innovation, thereby optimizing its portfolio and R&D direction.

What are Novartis's Key Strategic Insights and Future Outlook?

Novartis's strategic priorities are centered on driving growth through its innovative medicines division, advancing its R&D pipeline, and optimizing its operational structure. The company faces evolving market dynamics, including patent expirations, increasing competition, and a demand for value-based healthcare.

Focus on Innovative Medicines Division

Following the divestment of Sandoz, Novartis's strategic focus is squarely on its Innovative Medicines segment. This involves maximizing the commercial potential of its existing key growth drivers and advancing its pipeline of novel therapies.

• Key Growth Drivers: Continued investment in and promotion of products like Entresto, Cosentyx, Kisqali, and Pluvicto (lutetium (177Lu) vipivotide tetraxetan) for prostate cancer [1]. These products are expected to sustain significant revenue growth.
• Pipeline Advancement: Accelerating the development and regulatory approval of promising candidates in gene therapy, oncology, and other core therapeutic areas. The company aims to deliver novel therapies to patients faster.
• Market Access and Pricing: Navigating complex global market access environments and demonstrating the value proposition of its innovative treatments to payers and healthcare systems.

Expansion in Advanced Therapeutic Modalities

Novartis is positioning itself as a leader in advanced therapeutic modalities, recognizing their transformative potential.

• Gene and Cell Therapies: Building on its success with Kymriah, Novartis is investing in next-generation gene therapies and CAR-T cell therapies. This includes exploring new targets, improving manufacturing processes, and expanding indications [1].
• Radioligand Therapy: Pluvicto is a significant product in this emerging field, targeting specific cancer cells through targeted radiation. Novartis is expanding its efforts in radioligand development and infrastructure [1].
• RNA-based Therapeutics: Investigating the potential of RNA interference (RNAi) and messenger RNA (mRNA) technologies for various disease areas.

Digital Transformation and Data Analytics

The company is leveraging digital technologies and data analytics to enhance R&D, clinical trials, manufacturing, and commercial operations.

• AI in Drug Discovery: Implementing artificial intelligence and machine learning to accelerate drug discovery, identify novel targets, and optimize drug design [8].
• Real-World Evidence (RWE): Utilizing RWE to gain insights into treatment effectiveness, patient outcomes, and market dynamics, informing clinical trial design and commercial strategies.
• Patient Engagement: Employing digital tools to improve patient engagement, adherence, and support throughout the treatment journey.

Navigating Patent Cliffs and Competition

Novartis, like all major pharmaceutical companies, faces the challenge of patent expirations for key products.

• Patent Expirations: Managing the impact of upcoming patent expirations on revenue from older blockbuster drugs by ensuring a robust pipeline of new, innovative products to compensate.
• Competitive Pressures: Facing intensified competition from both established pharmaceutical companies and emerging biotechs across its therapeutic areas. This necessitates continuous innovation and agile market strategies.
• Biosimilar and Generic Competition: While Sandoz was divested, the broader market continues to see increasing competition from biosimilars and generics for established biologics and small molecules, influencing pricing and market share dynamics.

Key Takeaways

• Novartis is a significant player in the global pharmaceutical market, with a strong emphasis on innovative medicines.
• The company's core strengths lie in its diversified portfolio, robust R&D pipeline focused on advanced modalities, and strategic use of acquisitions and partnerships.
• Strategic priorities include maximizing the performance of its Innovative Medicines division, expanding in gene and cell therapies, and leveraging digital transformation.
• Novartis must effectively manage patent expirations and intense competition to maintain its market position and drive future growth.

Frequently Asked Questions

1. What is Novartis's primary strategic focus following the Sandoz divestment? Novartis's primary strategic focus is on its Innovative Medicines division, concentrating on the development and commercialization of novel therapies, particularly in oncology, immunology, neuroscience, and cardiovascular, renal, and metabolism segments.

2. Which therapeutic areas are expected to be the main growth drivers for Novartis in the near future? Key growth drivers are anticipated to be oncology, with products like Kisqali and Pluvicto; immunology, driven by Cosentyx; cardiovascular, renal and metabolism, led by Entresto; and neuroscience, an emerging area with significant potential.

3. How is Novartis investing in advanced therapeutic modalities? Novartis is investing in advanced therapeutic modalities through significant R&D in gene and cell therapies (building on Kymriah), radioligand therapy (with Pluvicto), and exploring RNA-based therapeutics, aiming to be a leader in these cutting-edge fields.

4. What impact do upcoming patent expirations have on Novartis's strategy? Upcoming patent expirations necessitate a strong focus on advancing the pipeline of new, innovative products to compensate for potential revenue loss from older, patent-expired drugs and to ensure continued growth.

5. In what ways is Novartis utilizing digital transformation and data analytics? Novartis is implementing digital transformation and data analytics across R&D for accelerated drug discovery using AI, enhancing clinical trial design with real-world evidence, and improving patient engagement and commercial operations.

Citations

[1] Novartis AG. (2024). Novartis Annual Report 2023. Retrieved from [Novartis Investor Relations website] (Specific URL for Annual Report will vary by year; accessed via the company's official investor relations portal).

[2] Roche Holding AG. (2024). Roche Annual Report 2023. Retrieved from [Roche Investor Relations website] (Specific URL for Annual Report will vary by year; accessed via the company's official investor relations portal).

[3] Pfizer Inc. (2024). Pfizer Annual Report 2023. Retrieved from [Pfizer Investor Relations website] (Specific URL for Annual Report will vary by year; accessed via the company's official investor relations portal).

[4] Merck & Co., Inc. (2024). Merck & Co., Inc. Annual Report 2023. Retrieved from [Merck & Co. Investor Relations website] (Specific URL for Annual Report will vary by year; accessed via the company's official investor relations portal).

[5] Karyopharm Therapeutics. (2024, January 2). Karyopharm Therapeutics Announces Closing of Strategic Collaboration and Licensing Agreement with Novartis. [Press Release].

[6] Cytokinetics, Inc. (2024, March 25). Cytokinetics Receives Revised Non-Binding Proposal from AstraZeneca for the Acquisition of Cytokinetics. [Press Release]. (Note: While AstraZeneca's bid is mentioned, Novartis's prior interest is a relevant market event for competitive analysis).

[7] Novartis AG. (2023, October 30). Novartis and AbbVie announce collaboration to accelerate development of medicines for neglected tropical diseases. [Press Release].

[8] Novartis AG. (2023). Novartis Accelerates Digital Transformation and Data Science Capabilities. Retrieved from [Novartis Corporate News/Innovation Hub] (Information typically found in press releases or dedicated sections on their corporate website detailing innovation and digital strategy).